Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65

Bio-Techne

Bio-Techne

TECH

0.00

Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ: TECH) with a Neutral rating and announces Price Target of $65.